Compugen To Present New Data At SITC 2023 Suggesting Leading Edge Of Anti-IL18 Binding Protein Antibody, COM503, In Treating Cancer
Portfolio Pulse from Benzinga Newsdesk
Compugen Ltd. (NASDAQ:CGEN) will present new data on its lead pre-clinical asset COM503, a potential first-in-class anti-IL18BP antibody, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2023. The data suggests that COM503 has a leading edge in inhibiting tumor growth while avoiding peripheral toxicity associated with administration of a cytokine. The company plans to file an IND in 2024.
October 31, 2023 | 1:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Compugen's new data on COM503 suggests it could be a leading treatment in cancer immunotherapy. This could potentially boost the company's stock in the short term as it indicates progress in their research and development.
The news is directly related to Compugen and its lead pre-clinical asset COM503. The positive data suggests that COM503 could be a leading treatment in cancer immunotherapy, which could potentially boost the company's stock in the short term as it indicates progress in their research and development.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100